OBJECTIVE: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). METHODS: Baseline and sequential cytokine levels (IL1, TNFalpha, IFNgamma, TGFbeta and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. RESULTS: At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFalpha levels were higher in responders than non-responders (p<0.01 and p<0.006, respectively). The two groups had similar baseline cytokine levels, apart from TNFalpha. Baseline CRP levels did not correlate significantly with baseline cytokine levels in responders, but a strong correlation was noted between baseline CRP and IL1, IFNgamma, and IL10 in non-responders. Apart from an early rise in TGFbeta and a decrease in IL10 in responders after the first infusion, sequential cytokine analysis for the first six months of treatment was not related to clinical disease activity measures. CONCLUSION: Although sequential cytokine analysis does not appear to be informative, baseline CRP and TNFalpha levels are useful markers of clinical response patterns in patients with AS treated with infliximab.
OBJECTIVE: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). METHODS: Baseline and sequential cytokine levels (IL1, TNFalpha, IFNgamma, TGFbeta and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. RESULTS: At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFalpha levels were higher in responders than non-responders (p<0.01 and p<0.006, respectively). The two groups had similar baseline cytokine levels, apart from TNFalpha. Baseline CRP levels did not correlate significantly with baseline cytokine levels in responders, but a strong correlation was noted between baseline CRP and IL1, IFNgamma, and IL10 in non-responders. Apart from an early rise in TGFbeta and a decrease in IL10 in responders after the first infusion, sequential cytokine analysis for the first six months of treatment was not related to clinical disease activity measures. CONCLUSION: Although sequential cytokine analysis does not appear to be informative, baseline CRP and TNFalpha levels are useful markers of clinical response patterns in patients with AS treated with infliximab.
Authors: Yuen Ling Elaine Au; Woon Sing Raymond Wong; Mo Yin Mok; Ho Yin Chung; Eric Chan; Chak Sing Lau Journal: Clin Rheumatol Date: 2014-07-01 Impact factor: 2.980
Authors: X B Wang; J J Ellis; D J Pennisi; X Song; J Batra; K Hollis; L A Bradbury; Z Li; T J Kenna; M A Brown Journal: Genes Immun Date: 2017-08-24 Impact factor: 2.676
Authors: Nathan Vastesaeger; Désirée van der Heijde; Robert D Inman; Yanxin Wang; Atul Deodhar; Benjamin Hsu; Mahboob U Rahman; Ben Dijkmans; Piet Geusens; Bert Vander Cruyssen; Eduardo Collantes; Joachim Sieper; Jürgen Braun Journal: Ann Rheum Dis Date: 2011-03-14 Impact factor: 19.103
Authors: Paul A C Lord; Tracey M Farragher; Mark Lunt; Kath D Watson; Deborah P M Symmons; Kimme L Hyrich Journal: Rheumatology (Oxford) Date: 2009-12-23 Impact factor: 7.580